AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05530564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-pressure pneumoperitoneum
Description: insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 8 to 10 mm Hg
Study NCT05530564 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard-pressure pneumoperitoneum
Description: insufflation of the abdomen for creation of pneumoperitoneum, pressure set points between 12 to 14 mm Hg
Study NCT00220285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin (SH L 749 , BAY86-5128)
Description: 0,3mCi/kg
Study NCT00220285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zevalin (SH L 749 , BAY86-5128)
Description: 0,4mCi/kg
Study NCT01045837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone and Gluten free diet
Description: Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
Study NCT01045837 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Gluten free diet
Description: Only gluten free diet will be given in this group
Study NCT00602472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: active
Study NCT00602472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to linagliptin 5 mg
Study NCT01189409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG then Senna
Description: Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
Study NCT01189409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna then PEG
Description: Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
Study NCT01938716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
Study NCT01981018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)
Description: ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~* Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~* Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~* Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print.
Study NCT04163952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT04163952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IM
Study NCT02289261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
Study NCT02289261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine plus dexmedetomidine
Description: Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
Study NCT03614520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Mineral water will be given as placebo
Study NCT03614520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark beer
Description: 250 mL of IPA beer (alcohol 8.5% vol)
Study NCT03614520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Beer
Description: 250 mL of blonde ale beer (alcohol 4,5% vol)
Study NCT02987790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Description: PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are \<35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak> 100mg / L), with a limit of seven days, if there is clinical improvement.
Study NCT02376699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) SEA-CD40
Description: Given intravenously; schedule is cohort-specific.
Study NCT02376699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously; schedule is cohort-specific.
Study NCT02376699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) SEA-CD40
Description: Given subcutaneously on Day 1 every 3 weeks
Study NCT02376699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
Study NCT02376699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 125 mg/m\^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
Study NCT02578706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75mg
Study NCT02578706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81 mg
Study NCT02578706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02578706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03630445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltooligosaccharides (IMOs)
Description: Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
Study NCT03630445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xtend® sucromalt
Description: Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
Study NCT03630445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of IMOs and Xtend® sucromalt
Description: A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
Study NCT03630445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw corn starch
Description: Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
Study NCT03630445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin
Description: Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
Study NCT02231905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-Sifrol®
Study NCT03085264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
Study NCT01695304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceramic water filter
Description: In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
Study NCT02986295 — intervention group
Intervention type: DEVICE
Intervention: BioMimeTM Stent, Ultimaster® Stent
Study NCT01829906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient programme
Study NCT01829906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient lifestyle programme
Study NCT00545259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study NCT01512615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex Cardiac rehabilitation
Description: Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
Study NCT01512615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Usual care, clinical control as provided by treating heart centre
Study NCT03423784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA BPX V3.3
Description: medical device containing HA
Study NCT03423784 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dentinox-Gel N
Description: Anaesthetic gel
Study NCT00055913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00055913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00055913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT06359353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 2 mg or 4 mg once daily~\* The dosage is determined based on cholesterol levels and the physician's decision.
Study NCT00343460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APF530
Description: Given subcutanously
Study NCT00343460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given IV and orally
Study NCT00343460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV and orally
Study NCT00343460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron Hydrochloride
Description: Given IV
Study NCT00343460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given subcutanously or IV
Study NCT00343460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given subcutanously or IV
Study NCT03475147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: eyeFusion
Description: Smartphone app based flicker fusion test.
Study NCT03475147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eyeFusion
Description: Smartphone app based flicker fusion test.
Study NCT03637738 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RIOP-Intrabeam® system
Description: The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.
Study NCT03637738 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery +RTE
Description: Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
Study NCT02769585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Description: Self-hypnosis
Study NCT02769585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDE training
Description: standard CDE training for an obese diabetic
Study NCT02362282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training
Description: Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
Study NCT02362282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
Study NCT02362282 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm training
Description: Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
Study NCT03702153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polypropylene mesh
Study NCT03702153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal wall reconstruction
Description: The repair of abdominal wall defects with polypropylene mesh
Study NCT06286488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaxigrip
Description: Evaluation of immunogenicity and tolerance of quadrivalent influenza vaccine in groups at risk of severe influenza, including obese adults, as well as in pregnant women (with assesment of antibodies in cord blood).
Study NCT01318460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan infusion
Description: Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
Study NCT01318460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Twenty-four hour administration of placebo
Study NCT04085289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study NCT04085289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT00646880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propiverine
Description: Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
Study NCT00646880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolterodine PR
Description: Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
Study NCT03292796 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prostaglandins
Study NCT01035801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-105
Description: Prandial Oral Insulin
Study NCT01035801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro Injection
Description: Insulin Lispro Injection
Study NCT04198714 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Pudendal block
Description: Administration of a pudendal block at the conclusion of vaginal surgery.
Study NCT04198714 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pudendal block
Description: Administration of a pudendal block at the conclusion of vaginal surgery.
Study NCT00328107 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine, recombinant Hemagglutinin
Description: 0.5mL dose for IM injection
Study NCT00328107 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza Vaccine, recombinant Hemagglutinin
Description: 0.5mL dose for IM injection
Study NCT04320316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crysvita (burosumab-twza) Treatment
Description: KRN23 is a fully human IgG1monoclonal antibody that binds to and inhibits the activity of FGF23, leading to an increase in serum phosphorus levels. It is a potential therapeutic candidate for the treatment of XLH, Tumor-Induced Osteomalacia (TIO), and the rickets/osteomalacia resulting from Epidermal Nevus Syndrome (ENS). All of these conditions are diseases of bone hypomineralization, caused by urinary phosphate wasting due to elevated levels of FGF23.
Study NCT03332706 — intervention group
Intervention type: OTHER
Intervention: observation
Description: after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
Study NCT02660372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imonogas
Description: Simethicone 120 mg in gel capsules
Study NCT02660372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Espumisan
Description: Simethicone 40 mg in gel capsules
Study NCT02037399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous dexamethasone
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
Study NCT02037399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous normal saline
Description: Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days.
Study NCT02454517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Undergo DPP lifestyle intervention
Study NCT02454517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo DPP lifestyle intervention
Study NCT02454517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive oral and written guidelines and meet with dietician
Study NCT02454517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02454517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02454517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02454517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02454517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02454517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01655732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment
Description: ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
Study NCT04560699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapeutic treatment and medical care
Description: Physiotherapeutic treatment twice a week for twelve weeks and medical care three times at baseline, week 13 and week 26